Drug Trial Radar · NCT01970865
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
364
Actual
Start
Jan 8, 2014
Primary completion
Mar 15, 2017
Study completion May 24, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
Conditions
- ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions
PF-06463922Drug
Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
CrizotinibDrug
Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1Time frame: Cycle 1 (21 days)
- Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)Time frame: 3 years
Locations
77 sites in 14 countries. Site status is shown where the registry gives one.
Highlands Oncology Group/Research
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Chao Family Comprehensive Cancer Center
Orange, California
UC Irvine Medical Center
Orange, California
University of Colorado Cancer Center
Aurora, Colorado
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavillion (AOP)
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
MDZ: Yale-New Haven Hospital
New Haven, Connecticut
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Karmanos Center Institute
Detroit, Michigan
Karmanos Cancer Institute
Farmington Hills, Michigan
Siteman Cancer Center-West County
Creve Coeur, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center-South County
St Louis, Missouri
Rockefeller Patient Pavilion - Memorial Sloan Kettering
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Rochester Regional Health System
Rochester, New York
SUNY Upstate Medical University
Syracuse, New York
The Ohio State University
Columbus, Ohio
The Ohio State University
Columbus, Ohio
The Ohio State University
Columbus, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute (Pharmacy)
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Chris O'Brien Lifehouse
Sydney, New South Wales, Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Chris O'Brien Lifehouse
Sydney Local Health District [rpa], New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
University Hospital Antwerp
Edegem, Belgium
British Columbia Cancer Agency-Vancouver Centre
Vancouver, British Columbia, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.